TITLE

Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?

AUTHOR(S)
Prasad, Vinay; Vandross, Andrae
PUB. DATE
April 2014
SOURCE
Journal of Cancer Research & Clinical Oncology;Apr2014, Vol. 140 Issue 4, p521
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
No abstract available.
ACCESSION #
94853390

 

Related Articles

  • Molecular Biomarkers for the Treatment of Lung Cancer: Personalized Therapy Beyond the EGFR Mutation. Suda, Kenichi; Mitsudomi, Tetsuya // Current Medical Literature: Lung Cancer;2013, Vol. 6 Issue 4, p91 

    The article discusses the use of molecular biomarkers to predict the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) to patients with lung cancer. The authors studied whether biomarkers are predictive or prognostic in lung cancer patients. They explained...

  • Cabozantinib prolonged PFS in patients with MTC. Calabro, Anthony; Costa, Samantha; Foster, Melissa // Endocrine Today;Oct2012, Vol. 10 Issue 10, p17 

    The article reports on the findings of a randomized Phase 3 study which revealed that cabozantinib significantly extended progression free survival in patients with progressing medullary thyroid carcinoma.

  • Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06). Koeberle, Dieter; Montemurro, Michael; Samaras, Panagiotis; Majno, Pietro; Simcock, Mathew; Limacher, Andreas; Lerch, Stefanie; Kovàcs, Katalin; Inauen, Roman; Hess, Vivianne; Saletti, Piercarlo; Borner, Markus; Roth, Arnaud; Bodoky, György // Oncologist;Mar2010, Vol. 15 Issue 3, p285 

    Background. Sunitinib (SU) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity. The objective of this trial was to demonstrate antitumor activity of continuous SU treatment in patients with hepatocellular carcinoma (HCC). Patients and Methods. Key eligibility...

  • ArQule Tumbles on Survival Miss in Lung Cancer Study. Shaffer, Catherine // BioWorld Today;10/3/2012, Vol. 23 Issue 192, p1 

    The article reports on the decline in the share price of ArQule Inc. on October 1, 2012 in response to the termination of its Phase III trial of ARQ 197 in patients with nonsquamous non-small-cell lung cancer (NSCLC). ArQule Chief Executive Officer (CEO) Paolo Pucci points out the failure of the...

  • Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review. XUEQIN CHEN; YUELONG PAN; SHIRONG ZHANG; DADONG CHEN; SHAOYU YANG; XIN LI; SHENGLIN MA // Oncology Letters;2014, Vol. 7 Issue 3, p878 

    Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of...

  • Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand? Shahait, Mohammed; Mukherji, Deborah; El-Hout, Yaser // Indian Journal of Urology;Apr-Jun2015, Vol. 31 Issue 2, p102 

    Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results, but a lower risk of chronic kidney disease, when compared with radical nephrectomy. However, there are limited data in the literature examining the safety of NSS in the setting of metastatic RCC. To...

  • Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer. Chrisoulidou, Alexandra; Mandanas, Stylianos; Margaritidou, Efterpi; Mathiopoulou, Lemonia; Boudina, Maria; Georgopoulos, Konstantinos; Pazaitou-Panayiotou, Kalliopi // OncoTargets & Therapy;Sep2015, Vol. 8, p2435 

    Objective: The aim of the present study was to assess patient compliance with tyrosine kinase inhibitor (TKI) treatment used for refractory and progressive thyroid cancer, in addition to the efficacy and serious adverse events associated with these agents. Methods: We retrospectively analyzed...

  • Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. Mitchell, Aaron P.; Harrison, Michael R.; Walker, Mark S.; George, Daniel J.; Abernethy, Amy P.; Hirsch, Bradford R. // Journal of Oncology Practice;Nov2015, Vol. 11 Issue 6, p491 

    The article reports on a 2015 study on the similarity of patients treated for metastatic renal cell cancer (mRCC) in routine clinical practice with those enrolled onto clinical trials. Results show that registry patients receiving tyrosine kinase inhibitors were more likely to have poor-risk...

  • 'Cabo' on Time for Exelixis, Fares Well; Wider Label Next? Osborne, Randy // BioWorld Today;11/30/2012, Vol. 23 Issue 232, p1 

    The article reports on the U.S. Food and Drug Administration (FDA) approval received by Exelixis Inc. for Cometriq or cabozantinib as treatment for medullary thyroid cancer (MTC). Positive results were obtained by Exelixis from a Phase III trial of cabozantinib in advanced MTC. Another Phase III...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics